$10.96-0.51 (-4.45%)
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.
Akari Therapeutics, Plc in the Healthcare sector is trading at $10.96 with a market capitalization of $24M. Wall Street consensus targets $28.50 (2 analysts), implying a +160.0% move over the next 12 months. The stock is currently near its 52-week low of $3.02, remaining 11.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$3.63Mβ | -$3.23Mβ | -$2.22Mβ | -$3.12Mβ | -$3.52M |
| Net Income | -$14.46Mβ | -$5.30Mβ | -$6.40Mβ | -$1.90Mβ | -$3.71M |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell ki...
European equities traded in the US as American depositary receipts opened the week slightly lower la
European equities traded in the US as American depositary receipts were trending lower late Thursday
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
European equities traded in the US as American depositary receipts were marginally higher late Tuesd
European equities traded in the US as American depositary receipts were trending lower in late Tuesd